Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update

Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update
Karyopharm SENTRY trial lauded at EHA

Karyopharm Therapeutics' new Phase 3 results from its SENTRY trial in myelofibrosis were featured in a late-breaking oral presentation at the EHA Annual Congress on June 14.

The EHA Scientific Program Committee selected these findings as one of the top presentations at the event, drawing significant attention from the hematology community. The recognition signals growing interest in Karyopharm Therapeutics' research in the field. Further details on the study and potential implications for treatment are expected from the conference proceedings.

Karyopharm Therapeutics previously presented Phase 3 SENTRY trial results in myelofibrosis at ASCO26. Those findings were also published in the Journal of Clinical Oncology. The company's ongoing data releases continue to draw attention from major medical conferences.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.